FOLH1 and neoplasm: Radioconjugates of ligands which bind to PSMA protein overexpressed on the surface of prostate have been routinely used for tumor imaging (68Ga-PSMA-11 ligand for PET/CT scanning), and, more importantly, the therapeutic 177Lu-PSMA-617 conjugate has been recently shown to reduce death rate and prolong lives of the patients with castration-resistant prostate cancer (CRPC) in phase III clinical study (VISION) [12,13].